As of Oct 21
| -0.10 / -1.32%|
The 8 analysts offering 12-month price forecasts for Amicus Therapeutics Inc have a median target of 12.50, with a high estimate of 19.00 and a low estimate of 9.00. The median estimate represents a +67.34% increase from the last price of 7.47.
The current consensus among 8 polled investment analysts is to Buy stock in Amicus Therapeutics Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.